Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.
Recent research regarding the structure and function of Bacillus anthracis lethal (LeTx) and edema (ETx) toxins provides growing insights into the pathophysiology and treatment of shock with this lethal bacteria. These are both binary-type toxins composed of protective antigen necessary for their cellular uptake and either lethal or edema factors, the toxigenic moieties. The primary cellular receptors for protective antigen have been identified and constructed and key steps in the extracellular processing and internalization of the toxins clarified. Consistent with the lethal factor's primary action as an intracellular endopeptidase targeting mitogen-activated protein kinase kinases, growing evidence indicates that shock with this toxin does not result from an excessive inflammatory response. In fact, the potent immunosuppressive effects of LeTx may actually contribute to the establishment and persistence of infection. Instead, shock with LeTx may be related to the direct injurious effects of lethal factor on endothelial cell function. Despite the importance of LeTx, very recent studies show that edema factor, a potent adenyl cyclase, has the ability to make a substantial contribution to shock caused by B. anthracis and works additively with LeTx. Furthermore, ETx may contribute to the immunosuppressive effects of LeTx. Therapies under development that target several different steps in the cellular uptake and function of these two toxins have been effective in in vitro and in vivo systems. Understanding how best to apply these agents clinically and how they interact with conventional treatments should be goals for future research.
Sherer
Kevin
K
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA.
Li
Yan
Y
Cui
Xizhong
X
Eichacker
Peter Q
PQ
D000818:Animals; D000881:Anthrax / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D000942:Antigens, Bacterial / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity*; D001408:Bacillus anthracis; D001427:Bacterial Toxins / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity*; D004195:Disease Models, Animal; D015195:Drug Design; D051381:Rats; D012772:Shock, Septic / Q000188:drug therapy / Q000276:immunology*
D000942:Antigens, Bacterial; D001427:Bacterial Toxins; C030325:anthrax toxin